Aprepitant for cough in lung cancer: A randomised placebo-controlled trial and mechanistic insights

This was a randomized, double-blind, crossover trial that evaluated the efficacy and safety of aprepitant in 20 lung cancer patients with cough. The primary endpoint was awake cough frequency collected using the Vitalograph VitaloJAK device; other endpoints included night-time and 24-hour cough frequency. Secondary endpoints included patient-reported changes in cough severity, cough frequency, and cough-related QoL.